OLOMOUC UNIVERSITY HOSPITAL – BEST RECRUITER IN THE PROFID EHRA TRIAL
The PROFID EHRA trial (NCT05665608) started in November 2023. It is the first randomised adequately powered assessment of the potential benefit of ICD therapy in myocardial infarction survivors with reduced LVEF under contemporary optimal medical therapy. Until now, almost 20 clinical sites in Austria, the Czech Republic, Germany and Spain have been opened for recruitment and …
8TH GENERAL ASSEMBLY MEETING
The 8th PROFID General Assembly Meeting was held on 18 April 2024 in Berlin, Germany. The PROFID partners presented the current status of their work packages, participated in the many important and fruitful discussions and thus ensured that the PROFID project continues successfully. The ambitious goals of PROFID, to change the role of prophylactic ICD …
PROFID AT EHRA CONGRESS 2024
The European Heart Rhythm Association (EHRA) Congress was held from 7 to 9 April 2024 in Berlin, Germany. The leading European EP conference brought together scientists, healthcare professionals and key opinion leaders involved in arrhythmia management from all around the world. PROFID and especially the PROFID EHRA trial had the great opportunity to be presented within several very …
PROFID TRANSFER TO CHARITÈ
With the move of the PROFID project coordinators, Prof. Gerhard Hindricks and Dr. Nikolaos Dagres, from Heart Center Leipzig to Deutsches Herzentrum der Charité (DHZC), Helios Health Institute and the third linked party Leipzig Heart Science terminated from the PROFID project and all tasks and responsibilities were transferred to Charité – Universitätsmedizin Berlin (CUB). Since …
FIRST PATIENTS ENROLLED IN THE PROFID EHRA TRIAL
The PROFID trial aims to reassess the role of routine prophylactic ICD implantation in patients with reduced LVEF ≤ 35% after myocardial infarction under contemporary OMT and is designed to be as close to routine clinical care as possible. The start of the PROFID clinical trial is a huge milestone.
THE START OF THE PROFID EHRA CLINICAL TRIAL
With the initiation of the first clinical study sites in Bad Segeberg and Rothenburg, Germany, and the enrolment of the first patients, the PROFID EHRA trial has finally started. From now on the 30-month recruitment period is underway. The PROFID EHRA trial (NCT05665608) is set to answer the question if routine implantation of an implantable …
PROFID AT ESC 2023
This year, PROFID had a marked presence at the European Society of Cardiology 2022 Congress, the world’s largest cardiovascular congress, during the session “Latest Science in Arrhythmias”. Project coordinator Dr. Nikolaos Dagres of the Leipzig Heart Institute presented the final results of the PROFID analysis.
PROFID EHRA COLLABORATION
We are pleased to announce that a very important step for the clinical trial has been taken. Since the start of the PROFID project in 2020, EHRA highly supports the project and the involved trial as a consortium partner via the ESC. This close cooperation between PROFID and EHRA has now been further strengthened; in …
Interview – THE START OF THE PROFID CLINICAL TRIAL
The PROFID trial aims to reassess the role of routine prophylactic ICD implantation in patients with reduced LVEF ≤ 35% after myocardial infarction under contemporary OMT and is designed to be as close to routine clinical care as possible. The start of the PROFID clinical trial is a huge milestone.